Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial

DOI record: { "DOI": "10.1007/s40121-021-00517-4", "ISSN": [ "2193-8229", "2193-6382" ], "URL": "http://dx.doi.org/10.1007/s40121-021-00517-4", "alternative-id": [ "517" ], "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "21 May 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "27 July 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "27 August 2021" } ], "author": [ { "affiliation": [], "family": "Shinkai", "given": "Masaharu", "sequence": "first" }, { "affiliation": [], "family": "Tsushima", "given": "Kenji", "sequence": "additional" }, { "affiliation": [], "family": "Tanaka", "given": "Shingo", "sequence": "additional" }, { "affiliation": [], "family": "Hagiwara", "given": "Eri", "sequence": "additional" }, { "affiliation": [], "family": "Tarumoto", "given": "Norihito", "sequence": "additional" }, { "affiliation": [], "family": "Kawada", "given": "Ichiro", "sequence": "additional" }, { "affiliation": [], "family": "Hirai", "given": "Yuji", "sequence": "additional" }, { "affiliation": [], "family": "Fujiwara", "given": "Sho", "sequence": "additional" }, { "affiliation": [], "family": "Komase", "given": "Yuko", "sequence": "additional" }, { "affiliation": [], "family": "Saraya", "given": "Takeshi", "sequence": "additional" }, { "affiliation": [], "family": "Koh", "given": "Hidefumi", "sequence": "additional" }, { "affiliation": [], "family": "Kagiyama", "given": "Naho", "sequence": "additional" }, { "affiliation": [], "family": "Shimada", "given": "Megumi", "sequence": "additional" }, { "affiliation": [], "family": "Kanou", "given": "Daiki", "sequence": "additional" }, { "affiliation": [], "family": "Antoku", "given": "Shinichi", "sequence": "additional" }, { "affiliation": [], "family": "Uchida", "given": "Yujiro", "sequence": "additional" }, { "affiliation": [], "family": "Tokue", "given": "Yutaka", "sequence": "additional" }, { "affiliation": [], "family": "Takamori", "given": "Mikio", "sequence": "additional" }, { "affiliation": [], "family": "Gon", "given": "Yasuhiro", "sequence": "additional" }, { "affiliation": [], "family": "Ie", "given": "Kenya", "sequence": "additional" }, { "affiliation": [], "family": "Yamazaki", "given": "Yoshitaka", "sequence": "additional" }, { "affiliation": [], "family": "Harada", "given": "Kazumasa", "sequence": "additional" }, { "affiliation": [], "family": "Miyao", "given": "Naoki", "sequence": "additional" }, { "affiliation": [], "family": "Naka", "given": "Takashi", "sequence": "additional" }, { "affiliation": [], "family": "Iwata", "given": "Mitsunaga", "sequence": "additional" }, { "affiliation": [], "family": "Nakagawa", "given": "Atsushi", "sequence": "additional" }, { "affiliation": [], "family": "Hiyama", "given": "Kazutoshi", "sequence": "additional" }, { "affiliation": [], "family": "Ogawa", "given": "Yoshihiko", "sequence": "additional" }, { "affiliation": [], "family": "Shinoda", "given": "Masahiro", "sequence": "additional" }, { "affiliation": [], "family": "Ota", "given": "Shinichiro", "sequence": "additional" }, { "affiliation": [], "family": "Hirouchi", "given": "Takatomo", "sequence": "additional" }, { "affiliation": [], "family": "Terada", "given": "Jiro", "sequence": "additional" }, { "affiliation": [], "family": "Kawano", "given": "Shuichi", "sequence": "additional" }, { "affiliation": [], "family": "Ogura", "given": "Takashi", "sequence": "additional" }, { "affiliation": [], "family": "Sakurai", "given": "Tsutomu", "sequence": "additional" }, { "affiliation": [], "family": "Matsumoto", "given": "Yoshihiko", "sequence": "additional" }, { "affiliation": [], "family": "Kunishima", "given": "Hiroyuki", "sequence": "additional" }, { "affiliation": [], "family": "Kobayashi", "given": "Osamu", "sequence": "additional" }, { "affiliation": [], "family": "Iwata", "given": "Satoshi", "sequence": "additional" } ], "container-title": "Infectious Diseases and Therapy", "container-title-short": "Infect Dis Ther", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2021, 8, 27 ] ], "date-time": "2021-08-27T18:02:36Z", "timestamp": 1630087356000 }, "deposited": { "date-parts": [ [ 2021, 11, 7 ] ], "date-time": "2021-11-07T14:15:07Z", "timestamp": 1636294507000 }, "funder": [ { "DOI": "10.13039/501100019949", "doi-asserted-by": "crossref", "name": "FUJIFILM Toyama Chemical CO" } ], "indexed": { "date-parts": [ [ 2024, 3, 28 ] ], "date-time": "2024-03-28T10:36:05Z", "timestamp": 1711622165879 }, "is-referenced-by-count": 49, "issue": "4", "issued": { "date-parts": [ [ 2021, 8, 27 ] ] }, "journal-issue": { "issue": "4", "published-print": { "date-parts": [ [ 2021, 12 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by-nc/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 8, 27 ] ], "date-time": "2021-08-27T00:00:00Z", "timestamp": 1630022400000 } }, { "URL": "https://creativecommons.org/licenses/by-nc/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 8, 27 ] ], "date-time": "2021-08-27T00:00:00Z", "timestamp": 1630022400000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1007/s40121-021-00517-4.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1007/s40121-021-00517-4/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1007/s40121-021-00517-4.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "page": "2489-2509", "prefix": "10.1007", "published": { "date-parts": [ [ 2021, 8, 27 ] ] }, "published-online": { "date-parts": [ [ 2021, 8, 27 ] ] }, "published-print": { "date-parts": [ [ 2021, 12 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "key": "517_CR1", "unstructured": "Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Upd. Geneva: World Health Organization. 2021. https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19---10-may-2021. Accessed 10 May 2021." }, { "DOI": "10.1128/AAC.00356-07", "author": "BB Gowen", "doi-asserted-by": "publisher", "first-page": "3168", "journal-title": "Antimicrob Agents Chemother", "key": "517_CR2", "unstructured": "Gowen BB, Wong MH, Jung KH, et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother. 2007;51:3168–76.", "volume": "51", "year": "2007" }, { "DOI": "10.1371/journal.pntd.0001342", "author": "M Mendenhall", "doi-asserted-by": "publisher", "first-page": "e1342", "journal-title": "PLoS Negl Trop Dis", "key": "517_CR3", "unstructured": "Mendenhall M, Russell A, Smee DF, et al. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever. PLoS Negl Trop Dis. 2011;5:e1342.", "volume": "5", "year": "2011" }, { "DOI": "10.1038/s41422-020-0282-0", "author": "M Wang", "doi-asserted-by": "publisher", "first-page": "269", "journal-title": "Cell Res", "key": "517_CR4", "unstructured": "Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–71.", "volume": "30", "year": "2020" }, { "DOI": "10.1038/s41467-020-18463-z", "author": "A Shanon", "doi-asserted-by": "publisher", "first-page": "4682", "journal-title": "Nat Commun", "key": "517_CR5", "unstructured": "Shanon A, Selisko B, Le NT, et al. Rapid incorporation of favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat Commun. 2020;11:4682.", "volume": "11", "year": "2020" }, { "DOI": "10.1074/jbc.RA120.013679", "author": "CJ Gordon", "doi-asserted-by": "publisher", "first-page": "6785", "journal-title": "J Biol Chem", "key": "517_CR6", "unstructured": "Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020;295:6785–97.", "volume": "295", "year": "2020" }, { "author": "Q Cai", "first-page": "1192", "journal-title": "Eng (Beijing)", "key": "517_CR7", "unstructured": "Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: An open-label control study. Eng (Beijing). 2020;6:1192–8.", "volume": "6", "year": "2020" }, { "key": "517_CR8", "unstructured": "Favipiravir Observational Study Group, Fujita Health University. Interim report of the Favipiravir Observational Study in Japan. 2020. https://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_favip_210419_eng.pdf." }, { "DOI": "10.1128/AAC.01051-06", "author": "RW Sidwell", "doi-asserted-by": "publisher", "first-page": "845", "journal-title": "Antimicrob Agents Chemother", "key": "517_CR9", "unstructured": "Sidwell RW, Barnard DL, Day CW, et al. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother. 2007;51:845–51.", "volume": "51", "year": "2007" }, { "DOI": "10.1371/journal.pntd.0009103", "author": "K Suemori", "doi-asserted-by": "publisher", "first-page": "e0009103", "journal-title": "PLoS Negl Trop Dis", "key": "517_CR10", "unstructured": "Suemori K, Saijo M, Yamanaka A, et al. A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome. PLoS Negl Trop Dis. 2021;22:e0009103.", "volume": "22", "year": "2021" }, { "DOI": "10.1111/j.0006-341X.1999.00853.x", "author": "L Cui", "doi-asserted-by": "publisher", "first-page": "853", "journal-title": "Biometrics", "key": "517_CR11", "unstructured": "Cui L, Hung HM, Wang SJ. Modification of sample size in group sequential clinical trials. Biometrics. 1999;55:853–7.", "volume": "55", "year": "1999" }, { "DOI": "10.2169/internalmedicine.5528-20", "author": "M Morikawa", "doi-asserted-by": "publisher", "first-page": "31", "journal-title": "Intern Med", "key": "517_CR12", "unstructured": "Morikawa M, Shinoda M, Ota S, et al. Clinical features of 154 COVID-19 patients and parameters for effective detection of pneumonia at the time of initial diagnosis in Japan. Intern Med. 2021;60:31–7.", "volume": "60", "year": "2021" }, { "DOI": "10.1016/j.ijid.2020.11.142", "author": "ZF Udwadia", "doi-asserted-by": "publisher", "first-page": "62", "journal-title": "Int J Infect Dis", "key": "517_CR13", "unstructured": "Udwadia ZF, Singh P, Barkate H, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2021;103:62–71.", "volume": "103", "year": "2021" }, { "author": "AA Ivashchenko", "first-page": "ciaa1176", "journal-title": "Clin Infect Dis", "key": "517_CR14", "unstructured": "Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial. Clin Infect Dis. 2020;2020:ciaa1176.", "volume": "2020", "year": "2020" }, { "DOI": "10.1128/AAC.01897-20", "author": "Y Doi", "doi-asserted-by": "publisher", "first-page": "e01897-20", "journal-title": "Antimicrob Agents Chemother", "key": "517_CR15", "unstructured": "Doi Y, Hibino M, Hase R, et al. A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother. 2020;64:e01897-20.", "volume": "64", "year": "2020" }, { "DOI": "10.1073/pnas.2014441117", "author": "SJF Kaptein", "doi-asserted-by": "publisher", "first-page": "26955", "journal-title": "Proc Natl Acad Sci USA", "key": "517_CR16", "unstructured": "Kaptein SJF, Jacobs S, Langendries L, et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc Natl Acad Sci USA. 2020;117:26955–65.", "volume": "117", "year": "2020" }, { "DOI": "10.1016/j.ejphar.2020.173634", "author": "Y Wang", "doi-asserted-by": "publisher", "first-page": "173634", "journal-title": "Eur J Pharmacol", "key": "517_CR17", "unstructured": "Wang Y, Chen L. Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment. Eur J Pharmacol. 2020;889:173634.", "volume": "889", "year": "2020" }, { "DOI": "10.1016/j.jiac.2021.04.013", "author": "S Fujii", "doi-asserted-by": "publisher", "first-page": "1051", "journal-title": "J Infect Chemother.", "key": "517_CR18", "unstructured": "Fujii S, Ibe Y, Ishigo T, et al. Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients. J Infect Chemother. 2021;27:1051–7.", "volume": "27", "year": "2021" }, { "DOI": "10.1016/S0140-6736(20)30566-3", "author": "F Zhou", "doi-asserted-by": "publisher", "first-page": "1054", "journal-title": "Lancet", "key": "517_CR19", "unstructured": "Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.", "volume": "395", "year": "2020" }, { "DOI": "10.1056/NEJMc2009787", "author": "TJ Oxley", "doi-asserted-by": "publisher", "first-page": "e60", "journal-title": "N Engl J Med", "key": "517_CR20", "unstructured": "Oxley TJ, Mocco J, Majidi S, et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med. 2020;382:e60.", "volume": "382", "year": "2020" }, { "DOI": "10.1038/s41586-020-2196-x", "author": "R Wölfel", "doi-asserted-by": "publisher", "first-page": "465", "journal-title": "Nature", "key": "517_CR21", "unstructured": "Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465–9.", "volume": "581", "year": "2020" }, { "DOI": "10.15585/mmwr.mm7003e2", "doi-asserted-by": "crossref", "key": "517_CR22", "unstructured": "Galloway SE, Paul P, MacCannell DR, et al. Emergence of SARS-CoV-2 B.1.1.7 Lineage—United States, December 29, 2020-January 12, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:95–9." }, { "DOI": "10.1016/j.cell.2020.07.012", "author": "Q Li", "doi-asserted-by": "publisher", "first-page": "1284", "journal-title": "Cell", "key": "517_CR23", "unstructured": "Li Q, Wu J, Nie J, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020;182:1284–94.", "volume": "182", "year": "2020" }, { "DOI": "10.1038/s41586-021-03471-w", "author": "S Cele", "doi-asserted-by": "publisher", "first-page": "142", "journal-title": "Nature", "key": "517_CR24", "unstructured": "Cele S, Gazy I, Jackson L, et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature. 2021;593:142–6.", "volume": "593", "year": "2021" } ], "reference-count": 24, "references-count": 24, "relation": {}, "resource": { "primary": { "URL": "https://link.springer.com/10.1007/s40121-021-00517-4" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Infectious Diseases", "Microbiology (medical)" ], "subtitle": [], "title": "Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "volume": "10" }